MONTREAL, QUEBEC–(Marketwired – Sep 9, 2016) – Knight Therapeutics Inc. (“Knight”)(TSX:GUD), a leading Canadian specialty pharmaceutical company, announced today that it has closed on its previously disclosed $1 million equity investment in 3D Signatures Inc. (“3D Signatures”), a biotechnology company with a mature technology platform for personalized medical diagnostics and prognostics, following the completion of a business combination and public listing transaction between 3D Signatures and Plicit Capital Corp.
Earlier this year, Knight entered into both an exclusive license and distribution agreement for the territories of Canada, Israel, Russia and CIS, Sub-Saharan Africa and the Caribbean, and an advisory services agreement with 3D Signatures. Knight CEO Jonathan Ross Goodman will join 3D Signatures’ advisory board.
“Knight is excited to be working alongside 3D Signatures, whose portfolio adds a new dimension to Knight’s product pipeline and stands to a leave a mark in the fight against cancer,” said Mr. Goodman.
Trading in the common shares of 3D Signatures on the TSX Venture Exchange is expected to begin on or about September 13, 2016 under the symbol “DXD”.
About 3D Signatures Inc.
3D Signatures Inc. is a personalized medicine company with a proprietary software platform based on the three-dimensional analysis of telomere organization. The technology is well developed and supported by 16 clinical studies on over 1,500 patients on 13 different cancers and Alzheimer’s disease. Depending on the application, the technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is designed to predict the course of disease and to personalize treatment for the individual patient.
About Knight Therapeutics Inc.
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. Knight Therapeutics Inc.’s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at www.gud-knight.com or www.sedar.com.
This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Information Form for the year ended December 31, 2015. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.